Navigation Links
Following a Good Start to the Year Shire Reaffirms Full Year 2008 Financial Guidance
Date:4/25/2008

REPLAGAL(R) - Fabry disease

- REPLAGAL is now approved in 41 countries and sales for the three months to March 31, 2008 were up 31% to $42.5 million (2007: $32.5 million).

Pipeline Highlights

VYVANSE (TM) - ADHD

- In March 2008 the Canadian new drug submission was accepted for filing for the treatment of ADHD in children.

- Shire plans to submit the regulatory filing for VYVANSE in Europe for the treatment of ADHD in children aged six to twelve in 2010.

JUVISTA(R) - Improvement of scar appearance

- In August 2007 Shire acquired the exclusive rights to develop and commercialize JUVISTA worldwide (with the exception of EU member states) from Renovo Limited ("Renovo"). JUVISTA, being investigated for the reduction of scarring in connection with surgery, is in Phase 2 development.

- Nine Phase 2 efficacy trials for JUVISTA have now been reported of which seven demonstrated statistically significant efficacy. Phase 2 clinical trials in multiple other surgery types are ongoing and are expected to report during 2008 and 2009.

- Shire is currently undertaking a comprehensive assessment of all results produced with JUVISTA to date and plans to seek external regulatory and other expert advice before confirming its path forward for JUVISTA in the United States and other potential markets.

HGT 2310 - Hunter syndrome with significant central nervous system symptoms

- Following the acceptance by the FDA in January 2008 of Shire's Investigational New Drug ("IND") application for idursulfase-IT, HGT 2310 (formerly referred to as ELAPRASE for Hunter syndrome patients with significant central nervous system symptoms - "Hunter CNS"), the Company is now in the process of planning clinical trials.

Business Highlights

Sale of non-core assets

- During Q1 2008, Shire completed the sale of a minority equity investment in Questcor Pharmaceuticals Inc. and disposed of certain hormone replaceme
'/>"/>

SOURCE Shire plc
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related biology technology :

1. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiogaphic Data Safety Monitoring Board Review
2. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiographic Data Safety Monitoring Board Review
3. Rosetta Genomics Announces Initiation of In Vivo Studies Following Successful Completion of First Milestone in MicroRNA-based Therapeutic Program for Liver Cancer
4. Sigma-Aldrich Achieves Double Accreditation as a Certified Reference Material Producer Following ISO/IEC 17025 and ISO Guide 34
5. In response to a New England Journal of Medicine article published yesterday and subsequent media coverage, Eli Lilly and Company issued the following statement:
6. Velcura Therapeutics, Inc. Can Begin Clinical Trials Following Successful Investigational New Drug Application to U.S. FDA
7. Cardiums Corgentin Preclinical Program Shows High Levels of Targeting to Acutely Ischemic Heart Muscle Following Intracoronary Infusion
8. Nereus Pharmaceuticals Initiates Clinical Trial of NPI-2358 in Non-Small Cell Lung Cancer Following Encouraging Phase 1 Data
9. ITSSD: Russia Can Secure Greatest Biotech Market Advances Following US, Not EU Innovation Model
10. Optherion, Inc. Completes $37 Million Start Up Financing
11. Actress Aida Turturro Tells Americans to Start Now to Talk With Their Healthcare Provider About Taking Control of Their Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2009)... University (NTU) signed the Memorandum of Understanding in ... (CNRS) and the Thales Group of Companies to ... parties are meeting again in Singapore to inaugurate ... , Located at the Research Techno Plaza, ... in science and technology to develop innovations in ...
(Date:12/16/2009)... Hahnemann among the Best in the Nation ... Hospital proudly announces it has been granted Magnet(R) ... Magnet Recognition Program(R). Magnet(R) is one of the ... center can achieve, and places Hahnemann among the ... have achieved this prestigious distinction. ,, At 9:00 ...
(Date:12/16/2009)... /PRNewswire/ -- Capitalizing on the continued ... an active venture capital market, leaders from BioCrossroads, ... Fund, Indiana University, Purdue University, the University of ... Suisse today announced the establishment of the INext ... funds. ,, Organized through BioCrossroads, Indiana,s initiative to ...
(Date:12/16/2009)... Inc. (Nasdaq: SQNM ), today announced the ... Pendarvis to its board of directors. ,, ... Buechler, Ph.D., was president, chief scientific officer and ... Dr. Buechler was Biosite,s director of chemistry. Prior ... research scientist for the diagnostics research and development ...
Breaking Biology Technology:New Singapore-French nanotech lab opens at NTU 2New Singapore-French nanotech lab opens at NTU 3Hahnemann University Hospital Granted Magnet(R) Status 2Hahnemann University Hospital Granted Magnet(R) Status 3Indiana Industry, University and Community Leaders Capitalize on Next Generation of State's Life Sciences Growth 2Indiana Industry, University and Community Leaders Capitalize on Next Generation of State's Life Sciences Growth 3Indiana Industry, University and Community Leaders Capitalize on Next Generation of State's Life Sciences Growth 4Indiana Industry, University and Community Leaders Capitalize on Next Generation of State's Life Sciences Growth 5Sequenom Appoints Two New Board Members 2Sequenom Appoints Two New Board Members 3
... industrys rallying cry of smaller and faster, the next ... come from microchips and data storage devices created out ... With innovative measurement techniques and new ways to position ... of the American Physical Society how they have improved ...
... 12 ,Exelixis, Inc. (Nasdaq: EXEL ) announced today ... of Exelixis, will present at the,Cowen and Company Annual ... p.m.,PT on Monday, March 17, 2008. Dr. Scangos will ... The presentation will be webcast and may be ...
... DIEGO, March 12 Biomatrica, the leader in ... a reagent that enhances PCR and RT-PCR performance ... amplification of genomic,DNA or RNA templates., PCRboost ... that are,traditionally difficult to amplify and present in ...
Other Biology Technology:Copolymers block out new approaches to microelectronics at NIST 2Biomatrica's PCRboost(TM) Enables 5-Fold Improvement in Amplification of Difficult Samples 2
(Date:12/16/2009)... FALLS CHURCH, Va., Dec. 9 ... today that the American Association for Laboratory ... Electrotechnical Commission (ISO/IEC) 17025:2005 accreditation to the ... the CSC Identity Labs located in Fairmont, ... biometrics test laboratory in the world to ...
(Date:12/15/2009)... The 2009 Frost & Sullivan European Border ... Sagem Securite (Safran Group) for its innovative ... the company,s expertise in advanced biometric technology ... value-added products to end users. ,, ... Securite has been involved in delivering identification ...
(Date:12/15/2009)... GAINESVILLE, Fla. When treating devastating brain diseases such ... medical bags to find something to help a patient. ... to help the vast majority of patients with ataxia ... and coordination. , University of Florida neurologists are trying ... million Challenge grant from the National Institute of Neurological ...
Breaking Biology News(10 mins):CSC's Identity Management and Biometric Test Lab Achieves ISO/IEC 17025 Accreditation 2Frost & Sullivan Recognises Sagem Securite for its Innovative Automated Border Control Systems 2Frost & Sullivan Recognises Sagem Securite for its Innovative Automated Border Control Systems 3Frost & Sullivan Recognises Sagem Securite for its Innovative Automated Border Control Systems 4UF to lead national effort to help patients with rare brain disease 2UF to lead national effort to help patients with rare brain disease 3In City of Fast Growing Tech Stars TeleTracking Shines Again 55624 1DaVita Offers Dialysis While Patients Sleep 55622 1DaVita Offers Dialysis While Patients Sleep 55622 2DaVita Offers Dialysis While Patients Sleep 55622 3Catholic Health Association Reaffirms Long Standing Commitment to Reform Health Care But Waits to Endorse Any Specific Bill 55620 1Catholic Health Association Reaffirms Long Standing Commitment to Reform Health Care But Waits to Endorse Any Specific Bill 55620 2
... clear example of how climate extremes can create conditions ... converge and bring about mass die-offs in wildlife. ... PLoS ONE, an online peer-reviewed research journal, researchers ... and 2001 that resulted in unusually high mortality in ...
... Scientists from Hungary, Germany and the U.K. have discovered that ... the active ingredient in marijuana (THC), but these play ... on "endocannabinoids" just published online in, and scheduled for the ... could lead to new drugs that treat skin conditions ranging ...
... faculty member who uses computational techniques to evaluate ... worldwide attention from other researchers. , Kevin C. ... engineering at the Florida A&M University-Florida State University ... determine how substances known as recombinant immunotoxins can ...
Other Biology News:FSU researcher using computers to hone cancer-fighting strategies 2
... ,Each upright model provides fast pull-down, ... uniformity for refrigerated blood. The BBR25 and ... for complete blood storage monitoring. Models BBR6, ... the HemaPro 101 alarm/monitor. All of these ...
... form of Tobacco Etch Virus (TEV) protease ... significantly more stable than native TEV protease, ... recognizes a seven amino acid (Glu-Asn-Leu-Tyr-Phe-Gln-Gly, cleaving ... for removing affinity tags from fusion proteins ...
S-100A10 (H-80)...
... S1 Nuclease degrades single-stranded DNA ... products. Double-stranded nucleic acids (DNA:DNA, DNA:RNA ... except with extremely high concentrations of ... to remove single-stranded termini from double-stranded ...
Biology Products: